THIS MATERIAL IS A MARKETING COMMUNICATION.
Monthly Commentary on Key Themes – Oct 2023
China Consumer Brand
China’s consumption recovery pace remains soft, but there are some signs of stabilization since August. August retail sales growth was +4.6% year-on-year (YoY), beating the street expectation of +3.0% YoY growth and also improved from +2.5% YoY in July. By category, gold, jewelry, and cosmetics led the acceleration, while electronics and appliances and sports and entertainment equipment fell into negative territory in August. We expect the overall consumption trend to have been similar in September.
September is generally a low season for many consumer products as it is a month between the summer holidays and the October Golden Week holiday. The market is currently focusing on the China National Day Golden Week as this is the second major public holiday in China since reopening. Golden week data shows that overall consumption remained similar to the May holidays, although it was slightly weaker than the government’s expectation. According to the Ministry of Culture and Tourism (MoCT), total tourism traffic (826 million) and revenues (RMB 753 billion) were up +4% and +2%, respectively, compared to 2019, during the 8 days (26 September to 6 October). Implied spending per traveller was RMB 912, which came in slightly better than MoCT’s expectation.
Chinese consumers spent more on travel and experience than tangible goods, which supported the restaurant and retail service industry. Domestic travel traffic was strong, with long-distance travel (within China) being a key theme, with many travellers spending on cultural and experience travel. According to the China Association of Performing Arts, live performance/show box office and audience were up +83% and +61% compared to 2019 (source: Jefferies). International traffic, including both inbound and outbound, reached 1.48 million people, which was 85% of 2019 level, due to the international flight capacity bottleneck, which still has only returned to 57% of 2019 level, according to Macquarie.
Overall retail sales showed a gradual recovery, with lower ticket items performing better. Sportswear saw an acceleration in demand since September, and Baijiu sales have been in line with the continuous polarization trend. For Baijiu, Golden Week sales have been in line, with sell-out improving gradually from the dragon boat festival, leading to lower channel inventory and slightly better wholesale prices.
Meanwhile, the polarization trend has continued in China. For instance, while overall baijiu consumption has been somewhat sluggish, the premium segment continued solid momentum with resilient growth for Moutai. At the same time, the low- to mid-end is expected to have double-digit growth, while there is more pressure on the mid- to high-end segment. The original case of Feitian Moutai’s wholesale price per bottle remained above RMB 3,000, and common Wuliangye’s wholesale price per bottle also remained flattish at around RMB 960 levels. Such polarization trend has also been seen across different consumer categories, including beer and sportswear.
We expect the government may introduce more policies to support the economy as they have set the pro-growth tone at the Politburo meeting in July. On the other hand, the valuation of many consumer companies has come down to more attractive levels, and thus, we are becoming more constructive on the China consumption theme.
Global X China EV & Battery
Auto sales increase and EV penetration stays solid in September: Based on the announcements of nine individual auto brands, their September sales data in aggregate amounted to 224k units, or +9.0% month-on-month (MoM). BYD reported September new energy vehicle (NEV) sales of 287.5k units, +43% YoY/+5% MoM. 9M23 NEV sales improved +76% YoY to 2.08 million units, of which overseas NEV passenger vehicle (PV) sales volume logged at 28,039 units (+12% MoM). Li Auto delivered 36,060 units of vehicles in September, +213% YoY and +3% MoM. 9M23 sales increased +181% YoY to 244,225 units and 3Q23 sales reached 105,108 units, beating 3Q23 sales guidance of 100-103k units. Nio September deliveries logged 15,641 units, +44% YoY/-19% MoM, and 9M23 total deliveries came in at 109,993 units, +33% YoY. 3Q23 sales logged 55,432 units, in line with 3Q23 sales guidance of 55-57k units. Xpeng September deliveries logged 15,310 units, +81% YoY/+12% MoM. 9M23 sales were -18% YoY to 81,443 units.
Battery production to grow in August: According to the China Automotive Battery Innovation Alliance (CABIA), China's power battery installation reached 34.9GWh in August, up 8.2% MoM and 25.7% YoY. China‘s power battery production reached 73.3GWh in August, up 20.2% MoM and 46.5% YoY. Implied months of China power battery inventories were 2.2x in August 2023 (vs 1.8x historical average months of power battery inventory). LFP battery installation accounted for 69.0% of total power battery installations in August, up 1.8ppt MoM and 6.9ppt YoY. CATL’s market share was 44.3% in August, up 2.5ppt MoM but down 2.5ppt YoY, while BYD's market share was down 2.0ppt MoM but up 5.1ppt YoY to 27.0%.
Battery material costs have declined further in September: China spot lithium carbonate price was around RMB 170k/t at the end of September, down by around RMB 40k/t or 20% MoM; GFEX futures were trading at RMB 130-150k/t; spodumene CIF dropped to USD 2,370/t and monthly average declined by over 20% as well; spread remained at a relatively low level. High-cost converters, especially those lepidolite based, are scaling back production as they struggle to make profit. Demand below expectation has been the key issue this year. The market stays calm without meaningful restocking for the National Day holiday, as cathode and downstream are cautious on price momentum. Spodumene price is still far above the cost curve and is expected to drop further with LC, thus reducing cost support for LC. Unless demand surprises on the upside, the vicious cycle is hard to stop until it hits spodumene cost and/or leads to a spodumene production cut.
Refreshed model from Tesla and newly launched model from Huawei: Tesla released its new Model 3 Highland version in September, with prices starting at RMB 259.9k. The manufacturer’s suggested retail price (MSRP), RMB 28k higher than the previous version, was higher than our expectation, which could help ease the intensifying price competition in China’s EV market. According to TroyTeslike, Tesla's order backlogs in China doubled MoM to around 36k units as of mid-September. The Huawei-backed AITO brand launched the new M7 SUV featuring Huawei's ADS 2.0 system, with map-free city navigation cruise assistance (NCA) functions said to cover the entire country in December. Huawei and Chery’s first co-developed model, Zhijie S7, which will benchmark Tesla Model S, will come to market in November. AITO’s next flagship, M9, is scheduled for launch in December, with a presale price range of RMB 500-600k.
Key stock movements:
BYD (002594.CH): BYD’s share price was down 5.1% in September, a positive contributor to the ETF. BYD outperformed most EV makers in September as select EV makers announced a new financing plan. BYD has a solid balance sheet and cash flow profile which implies a lower financing need. The company is negatively impacted by Europe’s new investigation into China’s auto exports, but the overall magnitude is small.
CATL (300750.CH): CATL’s share price was down 14.2% in September, a negative contributor to the ETF. The stock responded negatively to the news of Ford’s suspension of its new US battery plant construction, which was more driven by the US UAW labor union negotiation. Other operating performance has been quite resilient. The stock has showed resilient share price performance throughout the whole 3Q vs. the 2nd tier battery makers.
Ganfeng (002460.CH): Ganfeng’s share price was down 14.3% in September, a negative contributor to the ETF. Lithium stocks were the major negative contributor in September, given the recent sharp correction to lithium and lithium carbonate prices. The demand-supply condition stays unfavorable. There are also additional supply disruptions to Ganfeng’s asset portfolio.
Global X China Clean Energy
Solar – Polysilicon still searching for price floor; deflation across the whole supply chain: Solar polysilicon price grew to RMB 87/kg by end-September, from RMB 80/kg a month ago. Module prices are now at RMB 1.21/1.22/W for M10/G12, lower than the RMB 1.24/1.25/W a month ago. According to SCI99, solar glass prices remained stable week-on-week (WoW) at RMB 19.75/27.75/sqm for 2.0mm/3.2mm. Inventory levels decreased by 2.9% WoW to 17.27 days. Soda ash prices decreased by 2.9% WoW to RMB 3,300/t.
Inverter exports were down 10% MoM in August 2023. Total exports stood at USD 690 million in August (-10% MoM; -28% YoY). We believe the MoM fall was likely due to the ongoing inverter inventory pile-up in Europe that we were made aware of at Intersolar Europe. We see the MoM cut as a miss, given China cell/module exports posted a MoM recovery in August 2023.
Grid and power installation – Strong solar installation; grid capex taking a pause: In August, China added 26.4GW (+1.2x YoY) generation capacity, including 16.0GW solar (+1.4x YoY), 2.0GW thermal (+37.4% YoY), 2.6GW wind (+1.2x YoY), 1.7GW hydro (-30.1% YoY), and nil in nuclear. In 8M23, PRC’s new power generating capacity was 198.6GW (+1.1x YoY), comprising 113.2GW solar (+1.5x YoY), 34.3GW thermal (+72.9% YoY), 28.9GW wind (+79.2% YoY), 7.2GW hydro (-44.8% YoY), and 1.2GW nuclear (-47.8% YoY).
In August, capex for PRC power plants was +13.3% YoYto RMB 69.0 billion, comprising RMB 26.1 billion (+3.3% YoY) for solar, RMB 18.9 billion (+31.1% YoY) for wind, RMB 8.3 billion (+1.0x YoY) for nuclear, RMB 7.2 billion (-3.1% YoY) for thermal, and RMB 6.4 billion (+11.1% YoY) for hydro. Meanwhile, PRC’s power grid capex was +1.4% YoY to RMB 270.5 billion in 8M23, including -45.7% YoY to RMB 23.2 billion in August.
Global X China Robotics & AI
China data are showing some recovery in August: The latest monthly data points released by the National Bureau of Statistics reported on 15 September that China industrial robot production volumes were -19% YoY in August (-3% MoM vs. July and slightly better than past five years’ seasonality of -10% MoM); China machine tool production volumes were +0% YoY in August (+0% MoM vs. July and past five years’ seasonality of +1% MoM). Manufacturing FAI was +7% YoY in August (moderated vs. +4% in July). High-tech manufacturing fixed asset investment (FAI) dropped to +11% YoY in August (vs. +12% YoY in July). Railway FAI continued the recovery trend with +25% YoY in August (vs. +25% YoY in July).
August activity data (CPI/PPI) came in stronger than expected, pointing to a gradual improvement in sequential growth momentum amid the ongoing policy easing. Meanwhile, August orders announced by Inovance maintained 30+% YoY in August vs. 30-40% YoY in July; Haitian domestic orders improved to +15% MoM (+20% YoY), though it was due to an average selling price (ASP) adjustment. Yiheda mentioned a marginal pick up to 20% order YoY growth from 10% in May-July. EV component companies generally agree that their production plans for EV are solid, with a quarter-over-quarter (QoQ) sequential improvement in Q3. For solar exposure, the inverter export decline narrowed in August, and upstream component companies expect to see a further recovery of residential solar demand in Q4. For battery equipment companies, order trends have diversified as companies with more overseas orders have seen relatively better competitiveness.
JMTBA data suggest the bottom likely reached, but clear recovery driver lacking: Based on the final machine tool order data released by the Japan Machine Tool Builders’ Association (JMTBA) on 27 September. Global machine tool orders totalled ¥114.8 billion (-18% YoY, +0% MoM) in August 2023. Domestic Japan orders were ¥35.7 billion (-31% YoY/-9% MoM), a decrease from the previous month. On the other hand, overseas orders (ex-Japan) increased to ¥79 billion (-10% YoY/+5% MoM), up from the previous month, and as a result, overall orders were unchanged from the prior month. By region, orders declined versus the previous month in Japan and Europe, were mostly flat in North America, and were up a strong 17% MoM in China. While the outlook remains uncertain, we think overall orders have likely bottomed out, given that the absolute level in China turned up for the first time in four months after the sharp deceleration seen to date. However, we still do not see any industries or regions where we can expect a clear recovery in the near term, so we look for overall orders to trend near the bottom point for the time being, apart from a temporary upturn due to seasonal factors in September.
China Semiconductor/ Asia Semiconductor
Q2 revenue for top 10 global IC houses surges by 12.5% as Q3 on pace to set new record: Fuelled by an AI-driven inventory stocking frenzy across the supply chain, TrendForce reveals that Q2 revenue for the top 10 global integrated circuit (IC) design powerhouses soared to USD 38.1 billion, marking a 12.5% quarterly increase.
DRAM and NAND contract price stopped declining: September contract price of general-purpose PC DRAM has remained the same at USD 1.3 compared to that of last month, while the price is down 54.4% YoY. The contract price of general-purpose NAND for memory cards and USBs is USD 3.82 as of end-September, which is the same as that of last month. The current NAND contract price is down 11.2% YoY. It is reported that NAND companies are trying to increase the price, which could lead to a slight increase in ASP.
Huawei unveils new products at star-studded product launch: Chinese telecommunications giant Huawei once again drew public attention with its fall product launch on 25 September. The company introduced new tablets, watches, TVs, and high-end branded smartphones, specifically the “Ultimate Design” models.
Global X China Cloud Computing
August revenue growth for China software industry: China Software industry August revenues were +13% YoY, accelerating from July (+9% YoY), while still slower compared to June (18% YoY), leading 8M23 revenues to increase by 13.5% YoY. IT services growth outpaced the industry at 15% YoY in 8M23, driven by cloud computing and big data analysis services, embedded system software at +12% YoY; software products grew by +11% YoY, driven by industrial software at +13% YoY; and cybersecurity grew by +10% YoY. Net margin was down to 11.8% in August (vs. 12.8% in July).
July revenue growth for China telecom industry: August telco revenue grew 6.2% YoY, same as June, reversing the decelerating trend in 2Q23 (5% YoY). Mobile revenue grew 1.1% YoY, while fixed line revenue growth of 10.4% YoY was a new high since July 2021. 5G industrial internet revenue growth has seen 3 straight months of recovery to ~18% YoY in August, from ~12% in May, although cloud growth at ~35% remains at a historic low, similar to July.
Global X China Biotech
National Reimbursement Drug List (NRDL): The National Healthcare Security Administration (NHSA) held a H223 press conference in which it said the new list may be unveiled in early December 2023 and effective from 1 January 2024.
Generic drug evaluation application guide: The Center for Drug Evaluation (CDE) published on 25 September a draft soliciting comments on "Guidelines for Acceptance and Review of Quality and Efficacy Consistency Evaluation of Generic Drugs". The key update in this draft was the proposal of a three-year window for companies to submit generic drugs for evaluation that begins once the first generic drug of the same type has passed consistency evaluation; any applications submitted after this three-year window would not be accepted. However, drugs considered essential for clinical uses or in short supply may apply to provincial or municipal Medical Products Administration (MPA) for an extension.
Disclaimer & Information for Investors
No distribution, solicitation or advice: This document is provided for information and illustrative purposes and is intended for your use only. It is not a solicitation, offer or recommendation to buy or sell any security or other financial instrument. The information contained in this document has been provided as a general market commentary only and does not constitute any form of regulated financial advice, legal, tax or other regulated service.
The views and information discussed or referred in this document are as of the date of publication. Certain of the statements contained in this document are statements of future expectations and other forward-looking statements. Views, opinions and estimates may change without notice and are based on a number of assumptions which may or may not eventuate or prove to be accurate. Actual results, performance or events may differ materially from those in such statements. In addition, the opinions expressed may differ from those of other Mirae Asset Global Investments’ investment professionals.
Investment involves risk: Past performance is not indicative of future performance. It cannot be guaranteed that the performance of the Fund will generate a return and there may be circumstances where no return is generated or the amount invested is lost. It may not be suitable for persons unfamiliar with the underlying securities or who are unwilling or unable to bear the risk of loss and ownership of such investment. Before making any investment decision, investors should read the Prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Fund and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investment.
Sources: Information and opinions presented in this document have been obtained or derived from sources which in the opinion of Mirae Asset Global Investments (“MAGI”) are reliable, but we make no representation as to their accuracy or completeness. We accept no liability for a loss arising from the use of this document.
Products, services and information may not be available in your jurisdiction and may be offered by affiliates, subsidiaries and/or distributors of MAGI as stipulated by local laws and regulations. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction. This document is issued by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Securities and Futures Commission.
Information for EU investors pursuant to Regulation (EU) 2019/1156: This document is a marketing communication and is intended for Professional Investors only. A Prospectus is available for the Mirae Asset Global Discovery Fund (the “Company”) a société d'investissement à capital variable (SICAV) domiciled in Luxembourg structured as an umbrella with a number of sub-funds. Key Investor Information Documents (“KI(I)Ds”) are available for each share class of each of the sub-funds of the Company.
The Company’s Prospectus and the KI(I)Ds can be obtained from www.am.miraeasset.eu/fund-literature . The Prospectus is available in English, French, German, and Danish, while the KI(I)Ds are available in one of the official languages of each of the EU Member States into which each sub-fund has been notified for marketing under the Directive 2009/65/EC (the “UCITS Directive”). Please refer to the Prospectus and the KI(I)D before making any final investment decisions.
A summary of investor rights is available in English from www.am.miraeasset.eu/investor-rights-summary/.
The sub-funds of the Company are currently notified for marketing into a number of EU Member States under the UCITS Directive. FundRock Management Company can terminate such notifications for any share class and/or sub-fund of the Company at any time using the process contained in Article 93a of the UCITS Directive.
Hong Kong: It is intended is for Hong Kong investors. Before making any investment decision to invest in the Fund, Investors should read the Fund’s Prospectus and the information for Hong Kong investors (of applicable) of the Fund for details and the risk factors. The individual and Mirae Asset Global Investments (Hong Kong) Limited may hold the individual securities mentioned. This document is issued by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Securities and Futures Commission.
Singapore: It is not intended for general public distribution. The investment is designed for Institutional investors and/or Accredited Investors as defined under the Securities and Futures Act of Singapore. This document is issued by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Monetary Authority of Singapore. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction.
Australia: The information contained in this document is provided by Mirae Asset Global Investments (HK) Limited (“MAGIHK”), which is exempted from the requirement to hold an Australian financial services license under the Corporations Act 2001 (Cth) (Corporations Act) pursuant to ASIC Class Order 03/1103 (Class Order) in respect of the financial services it provides to wholesale clients (as defined in the Corporations Act) in Australia. MAGIHK is regulated by the Securities and Futures Commission of Hong Kong under Hong Kong laws, which differ from Australian laws. Pursuant to the Class Order, this document and any information regarding MAGIHK and its products is strictly provided to and intended for Australian wholesale clients only. The contents of this document is prepared by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Australian Investments & Securities Commission.
Swiss investors: This document is intended for Professional Investors only. This is an advertising document. The Swiss Representative is 1741 Fund Solutions AG, Burggraben 16, CH-9000 St. Gallen. The Swiss Paying Agent is Tellco AG, Bahnhofstrasse 4, CH-6431 Schwyz. The Prospectus and the Supplements of the Funds, the KI(I)Ds, the Memorandum and Articles of Association as well as the annual and interim reports of the Company are available free of charge from the Swiss Representative.
UK investors: This document is intended for Professional Investors only. The Company is a Luxembourg registered UCITS, recognised in the UK under section 264 of the Financial Services and Markets Act 2000. Compensation from the UK Financial Services Compensation Scheme will not be available in respect of the Fund. The taxation position affecting UK investors is outlined in the Prospectus. This document has been approved for issue in the United Kingdom by Mirae Asset Global Investments (UK) Ltd, a company incorporated in England & Wales with registered number 06044802, and having its registered office at 4th Floor, 4-6 Royal Exchange Buildings, London EC3V 3NL, United Kingdom. Mirae Asset Global Investments (UK) Ltd. is authorised and regulated by the Financial Conduct Authority with firm reference number 467535.
Copyright 2024. All rights reserved. No part of this document may be reproduced in any form, or referred to in any other publication, without express written permission of Mirae Asset Global Investments (Hong Kong) Limited.